Ischemia in type 2 diabetes: Tissue selectivity of sulfonylureas and clinical implications

Metabolism: Clinical and Experimental

Volumn 52, Issue , 2003, Pages 3-5

  Wascher, Thomas C ^a   Boes, Ursula ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ADENOSINE TRIPHOSPHATASE (POTASSIUM); DIAZOXIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; INSULIN; METFORMIN; NICORANDIL; POTASSIUM CHANNEL; POTASSIUM CHANNEL AFFECTING AGENT; RECEPTOR SUBUNIT; SULFONYLUREA DERIVATIVE; SULFONYLUREA RECEPTOR;

ANGINA PECTORIS; BINDING AFFINITY; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG INHIBITION; ENDOTHELIUM INJURY; HEART INFARCTION PREVENTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HUMAN; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; TISSUE SPECIFICITY;

EID: 0042386751     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(03)00211-7     Document Type: Article

References (41)

1. Groop LC: Sulfonylureas in NIDDM. Diabetes Care 15:737-753, 1992
2. Garratt KN, Brady PA, Hassinger NL, et al: Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 33:119-124, 1999
3. + channels and insulin secretion: Their role in health and disease. Diabetologia 42:903-919, 1999
4. Nichols CG, Ripoll C, Lederer WJ: ATP-sensitive potassium channel modulation of the guinea pig ventricular action potential and contraction. Circ Res 68:280-287, 1991
5. Brayden JE: Hyperpolarization and relaxation of resistance arteries in response to adenosine diphosphate. Distribution and mechanism of action. Circ Res 69:1415-1420, 1991
6. + channels protect the myocardium against ischemic/reperfusion damage. Circ Res 69:571-581, 1991
7. Seino S: ATP-sensitive potassium channels: A model of heteromultimetric potassium channel/receptor assemblies. Ann Rev Physiol 61:337-362, 1999
8. ATP channels. Physiol Rev 78:227-245, 1998
9. ATP: An inward rectifier subunit plus the sulfonylurea receptor. Science 270:1166-1170, 1995
10. ATP channels. J Diabetes Complications 14:192-196, 2000
11. ATP channels in mouse isolated pancreatic beta cells but not in rat heart or arterial smooth muscle cells. Diabetologia 44:1019-1025, 2001
12. ATP channel openers. Fundam Clin Pharmacol 17:61-69, 2003
13. Reimann F, Ashcroft FM, Gribble FM: Structural basis for the interference between nicorandil and sulfonylurea action. Diabetes 50:2253-2259, 2001
14. Chilian W, Eastham C, Marcus M: Microvascular distribution of coronary vascular resistance in beating left ventricle. Am J Physiol 251:H779-H786, 1986
15. Chowienczyk PJ, Watts GF, Cockcroft JR, Ritter JM: Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet 340:1430-1432, 1992
16. Jones CJH, Kuo L, Davis MJ, et al: Role of nitric oxide in the coronary microvascular responses to adenosine and increased metabolic demand. Circulation 91:1807-1813, 1995
17. Cannon R, Schenke W, Leon M, et al: Limited coronary flow reserve after dipyridamole in patients with ergovine-induced coronary vasoconstriction. Circulation 75:163-174, 1987
18. Harrison DG: Endothelial dysfunction in the coronary microcirculation: A new clinical entity or an experimental finding? J Clin Invest 91:1-2, 1993
19. Zeiher A, Drexler H, Wollschläger H, et al: Progressive endothelial dysfunction with different stages of early coronary atherosclerosis. Circulation 83:391-401, 1991
20. Zeiher AM, Krause T, Schächinger V, et al: Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation 91:2345-2352, 1995
21. Hasdai D, Gibbons RJ, Holmes DR, et al: Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. Circulation 96:3390-3395, 1997
22. Bache RJ: Vasodilator reserve. A functional assessment of coronary health. Circulation 98:1257-1260, 1998
23. Baliga RR, Rosen SD, Camici PG, et al: Regional myocardial blood flow redistribution as a cause of postprandial angina pectoris. Circulation 97:1144-1149, 1998
24. Tagawa T, Imaizumi T, Endo T, et al: Role of nitric oxide in reactive hyperemia in human forearm vessels. Circulation 90:2285-2290, 1994
25. Carlsson I, Sollevi A, Wennmalm A: The role of myogenic relaxation adenosine and prostaglandins in human forearm reactive hyperemia. J Physiol 389:147-161, 1987
26. Kosmas EN, Levy RD, Hussain SNA: Acute effects of glyburide on the regulation of peripheral blood flow in normal humans. Eur J Pharmacol 274:193-199, 1995
27. ATP channels in man. Diabetologia 39:1083-1090, 1996
28. Cleveland JC, Meldrum DR, Cain BS, et al: Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Circulation 96:29-32, 1997
29. Bijlstra PJ, Russel FGM, Thien T, et al: Effects of tolbutamide on vascular ATP-sensitive potassium channels in humans. Horm Metab Res 28:512-516, 1996
30. ATP channel blockade by sulphonylurea derivatives in humans. Eur J Clin Invest 32:163-171, 2002
31. Abbink EJ, Pickkers P, Jansen Van Rosendaal A, et al: Vascular effects of glibenclamide vs. glimepiride and metformin in type-2 diabetic patients. Diabet Med 19:136-143, 2002
32. ATP channel blockade by glibenclamide, but not by acarbose in patients with type-II diabetes. Clin Sci 102:307-314, 2002
33. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
34. Wascher TC, Boes U: Different effects of glibenclamide and gliclazide on forearm vascular reserve in type 2 diabetic patients. Diabetologia 45:854, 2002 (suppl 2, abstr A275)
35. Wikstrom G, Malmberg K, Rydén L: Improved knowledge of antidiabetic treatment: A necessity for the modern cardiologist. Eur Heart J 20:403-405, 1999
36. The UKPDS Study Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
37. Klepzig H, Kobert G, Matter C, et al: Sulfonylureas and ischemic preconditioning - A double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 20:439-446, 1999
38. Jennings PE, Scott NA, Saniabadi AR, et al: Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: Clinical assessment. Metabolism 41:36-39, 1992
39. Noda Y, Mori A, Packer L: Gliclazide scavenges hydroxyl, superoxide and nitric oxide radicals: An ESR study. Res Commun Mol Pathol Pharmacol 96:115-124, 1997
40. O'Brien R, Luo M: The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro. Metabolism 12:22-25, 1997 (suppl 1)
41. Tessier D, Maheux P, Khalil A, et al: Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Metabolism 48:897-903, 1999